Related Experiment Video
Updated: May 19, 2026
04:43
Quantification of Adeno-Associated Viral Genomes in Purified Vector Samples by Digital Droplet Polymerase Chain Reaction
Published on: October 11, 2024
Recombinant adeno-associated virus: clinical application and development as a gene-therapy vector
Ping-Jie Xiao1, Thomas B Lentz, R Jude Samulski
1Gene Therapy Center, University of North Carolina at Chapel Hill, 7119 Thurston Bowles, 104 Manning Dr. Chapel Hill, NC 27599-7352, USA.
Therapeutic Delivery
|August 21, 2012
Summary
Gene therapy using recombinant adeno-associated virus (rAAV) shows promise for treating diseases. Engineering the viral capsid improves targeting and efficiency for better clinical outcomes.
Area of Science:
- Biotechnology
- Molecular Biology
- Gene Therapy
Background:
- Gene therapy is evolving beyond monogenic disorders.
- Recombinant adeno-associated virus (rAAV) is a leading gene delivery vector.
- rAAV demonstrates a strong safety profile and clinical trial success.
Purpose of the Study:
- To review the biology of rAAV as a gene therapy vector.
- To compare rAAV with other gene delivery methods.
- To discuss the clinical application status of rAAV.
Main Methods:
- Review of rAAV biology and vector characteristics.
- Analysis of rAAV clinical trial data.
- Exploration of vector engineering strategies.
Main Results:
- rAAV offers advantages over other gene delivery systems.
- Clinical trials show significant progress for rAAV-based therapies.
- Vector engineering can enhance tissue targeting and transduction.
Conclusions:
- rAAV is a powerful tool for gene therapy.
- Ongoing research focuses on optimizing rAAV vectors.
- Capsid modification is key to improving rAAV efficacy and specificity.
